Publications by authors named "Mark Bagarazzi"

Claim this Profile
S
Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
Pablo Tebas, Christine C Roberts, Kar Muthumani, Emma L Reuschel, Sagar B Kudchodkar, Mark Bagarazzi

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults.
Srilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, Yiwen Lu, Xue Han, Mark L Bagarazzi

Vaccines (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Yasmin Hasan, Larissa Furtado, Ana Tergas, Nita Lee, Rebecca Brooks, Mark Bagarazzi

Int J Radiat Oncol Biol Phys· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
Stephen C De Rosa, Srilatha Edupuganti, Yunda Huang, Xue Han, Marnie Elizaga, Mark L Bagarazzi

JCI Insight· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Neal D Shore, Matthew P Morrow, Trevor McMullan, Kimberly A Kraynyak, Albert Sylvester, Mark L Bagarazzi

Mol Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Kayvon Modjarrad, Christine C Roberts, Kristin T Mills, Amy R Castellano, Kristopher Paolino, Mark Bagarazzi

Lancet Infect Dis· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
Pablo Tebas, Kimberly A Kraynyak, Ami Patel, Joel N Maslow, Matthew P Morrow, Mark Bagarazzi

J Infect Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
Kimberly A Kraynyak, Angela Bodles-Brakhop, Mark Bagarazzi

Curr Top Microbiol Immunol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Charu Aggarwal, Roger B Cohen, Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, Mark L Bagarazzi

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, Michael Dallas, Dawson Knoblock, Mark L Bagarazzi

Clin Cancer Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.
Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, Xuefei Shen, Dinah Amante, Mark L Bagarazzi

Mol Ther Oncolytics· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials.
Christopher L Jenkins, Mark L Bagarazzi, Hans-Peter Kiem, Arnold J Levine, Dale Ando

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects.
Jessica C Lee, Stanley Menacherry, Malissa C Diehl, Mary D Giffear, C Jo White, Mark L Bagarazzi

Clin Pharmacol Drug Dev· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Cornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, Xuefei Shen, Michael Dallas, Mark L Bagarazzi

Lancet· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
Matthew P Morrow, Pablo Tebas, Jian Yan, Lorenzo Ramirez, Anna Slager, Mark L Bagarazzi

Mol Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
Malissa C Diehl, Jessica C Lee, Stephen E Daniels, Pablo Tebas, Amir S Khan, Mark L Bagarazzi

Hum Vaccin Immunother· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.
Mark L Bagarazzi, Jian Yan, Matthew P Morrow, Xuefei Shen, R Lamar Parker

Sci Transl Med· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next generation DNA vaccines for HIV-1.
J D Boyer, Michael Chattergoon, Karuppiah Muthumani, Sagar Kudchodkar, Joseph Kim, Mark Bagarazzi

J Liposome Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques.
Karuppiah Muthumani, Mark Bagarazzi, Dan Conway, Daniel S Hwang, Kelledy Manson

Vaccine· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis